Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

WALTHAM, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities 2019 Life Sciences Conference on June 19, 2019 at 9:30 a.m. Eastern Time.

The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.  

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com.

Contact:

William B. BoniVP, Investor RelationsCorp. CommunicationsMinerva Neurosciences, Inc.(617) 600-7376

You May Also Be Interested In

• Alley Cat Allies Delivers Emergency Water and Cat Food to Support San Juan Cats and Caregivers During Puerto Rico Water Crisis
• o2 DEX Launches Turbo Accounts, Replacing Prop Firm Evaluations With Instant Trading Capital
• bolt Delivers First AI-Powered Insurance Distribution Platform for All Lines, Including Admitted, E&S and Wholesale Markets